A host of promising agents for myeloma: melflufen, filanesib, trametinib, selinexor
Exciting novel AML treatment: venetoclax plus cobimetinib or idasanutlin in elderly patients
Myeloma 2017 day 2 highlights: MRD, targeted therapies and imaging advances
Gareth Morgan et al.
Perspectives in AML treatment: targeting apoptosis without chemotherapy by using BH3-mimetics
Developing targeted therapies to combine with venetoclax in acute myeloid leukemia (AML)